AR066478A1 - Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones - Google Patents
Derivados heterociclicos sustituidos y su uso farmaceutico y composicionesInfo
- Publication number
- AR066478A1 AR066478A1 ARP080101937A ARP080101937A AR066478A1 AR 066478 A1 AR066478 A1 AR 066478A1 AR P080101937 A ARP080101937 A AR P080101937A AR P080101937 A ARP080101937 A AR P080101937A AR 066478 A1 AR066478 A1 AR 066478A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- cycloalkyl
- halogen
- hydroxyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Su preparacion y su uso como agentes antimicrobianos. Reivindicacion 1: Un compuesto de formula (1) o una sal o profármaco farmacéuticamente aceptable del mismo, o un hidrato o solvato de dicho compuesto, sal o profármaco, en la que: al menos unode X1, X2, X3, X4, X5 o X6 se selecciona de N o N-oxido y los restantes se seleccionan de N o CR1; cada R1 se selecciona independientemente de hidrogeno, halogeno, ciano, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, amino, hidroxilo, tiol oalquiltio C1-6; R2 se selecciona independientemente de hidrogeno, hidroxilo, halogeno, amino, alquilo C1-6, alquiltio C1-6, cicloalquilo C3-10, cicloalquil C3-10-alquilo C1-6, alquil C1-6-cicloalquilo C3-10, heterocicIoalquilo C2-9, heterociclo C2-9-alquilo C1-6, ariloxi C6-10, heterocicloxi C2-9, heterociclo C2-9-alcoxi C1-6, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, fluorometilo, difluorometilo, trifluorometilo, fluorometoxi, difluorometoxi, trifluorometoxi, cicloalquiloxi C3-10, cicloalquiltioC3-10, aciloxi C1-6, ciano, nitro, en el que cualquiera de los grupos anteriormente mencionados (con la excepcion de hidrogeno, halogeno, ciano, hidroxilo y nitro) está opcionalmente sustituido con al menos un resto seleccionado de alquilo C1-6,cicloalquilo C3-10, alcoxi C1-6, cicloalcoxi C3-10, arilo C6-10, heteroarilo C5-9, carboxilo, alquiI C1-6oxicarbonilo, cicloalquil C3-10oxicarbonilo, acilo C1-6, halogeno, haloalquilo C1-6, haloalcoxi C1-6, alquilsulfonilo C1-6, aminocarbonilo,(alquil C1-6)aminocarbonilo, (alquil C1-6)2 aminocarbonilo, hidroxilo, heterocicloxi C2-9, ariloxi C6-10 o aciloxi C1-6; X7 se selecciona de O, NR5, CH2, -S-, SO o SO2 o -CR5H-; R4 se selecciona de hidrogeno, hidroxilo, alcoxi C1-6, fluoro, NH2,(alquil C1-6)NH-, (alquil C1-6)2N- o heterocicloalquilo C2-9, ciano o alquiltio C1-6; R5 se selecciona de hidrogeno; alquilo C1-6, alquil C1-6oxicarbonilo, aminocarbonilo, alquilsulfonilo C1-6 o alquil C1-6carbonilo; D es como en formula (2), C seselecciona de formula (3) en la ô ö indica un punto de union; Y1 es CR6 en la que R6 se selecciona de hidrogeno, hidroxilo, halogeno, alquilo C1-6 o R7 o Y1 es N y en los que uno de los átomos de carbono del anillo de cada uno de los gruposanulares C anteriores, junto con el grupo al que está unido, puede estar opcionalmente reemplazado por -C(O)-; cada R7 se selecciona independientemente de hidrogeno, halogeno, hidroxilo, alquilo C1-6, alcoxi C1-6, trifluorometilo, trifluorometoxi oamino, a condicion de que cuando Y1 es N y R7 es hidroxilo, alcoxi C1-6, amino, trifluorometoxi o halogeno, R7 no puede localizarse en un átomo adyacente a Y1; R8 se selecciona de arilo C6-10, ariloxi C6-10, aril C6-10-alquilo C1-6, aril C6-10-alcoxi C1-6, cicloalquilo C3-10, cicloalcoxi C3-10, cicloalquil C3-10-alcoxi C1-6, cicloalquil C3-10-alquilo C1-6, heteroaril C5-9-alquilo C1-6, heteroarilo C5-9, heteroaril C5-9-alcoxi C1-6, heteroariloxi C5-9, cicloalcoxi C3-10-alquilo C1-6,heterocicloalquilo C2-9, heterocicloxi C2-9, heterociclo C2-9-alquilo C1-6, heterociclo C2-9-alcoxi C1-6, en los que cualquiera de los grupos anteriormente mencionados puede estar opcionalmente sustituido con 1 a 4 restos seleccionados cada unoindependientemente de halogeno, alquilo C1-6, aIcoxi C1-6, alcoxi C1-6-alquilo C1-6, carboxilo, haloalquilo C1-6, haloalcoxi C1-6, tiol, alquiltio C1-6, hidroxilo, nitro, ciano amino, mono- o dialquilamino C1-6, arilo C6-10, heteroarilo C5-9,alcoxiC1-6carbonilo, alcoxi C1-6-carbonilalquilo C1-6, cicloalquilo C3-10, alquilC1-6carbonilo, alquilsulfinilo C1-6, alquilsulfonilo C1-6, aminocarbonilo, mono- y dialquil C1-6aminocarbonilo, aciltio C1-6 o aciloxi C1-6; o R7 y R8, junto con losátomos a los que están unidos, forman un sistema anular saturado o insaturado o aromático de 3 a 8 miembros que puede ser monociclico o bicíclico, en el que dicho sistema anular puede contener opcionalmente al menos un heteroátomo seleccionado denitrogeno, oxigeno o azufre, y en el que dicho sistema anular puede estar opcionalmente sustituido con 1 a 4 restos seleccionados cada uno independientemente de hidroxilo, halogeno, ciano, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-10, cicloalcoxi C3-10, formilo, acilo C1-6, alcoxi C1-6-carbonilo, heterocicloalquilo C2-9, arilo C6-10 o heteroarilo C5-C9; R9 se selecciona de carboxilo, alcoxi C1-6-carbonilo, aminocarbonilo, alquilC1-6aminocarbonilo, aIquil C1-6sulfonilaminocarbonilo, hidroxilo, hidroximetilo o tetrazol; R10 se selecciona de hidrogeno, halogeno, hidroxilo, alquilo C1-6 o haloalquilo C1-6; n es 0,1, 2 o 3; m es 0, 1, 2 o 3; p es 0 o 1; y q es 0, 1o 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91690607P | 2007-05-09 | 2007-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR066478A1 true AR066478A1 (es) | 2009-08-19 |
Family
ID=39865577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080101937A AR066478A1 (es) | 2007-05-09 | 2008-05-07 | Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones |
Country Status (17)
Country | Link |
---|---|
US (3) | US20080280879A1 (es) |
EP (2) | EP2155716A2 (es) |
JP (1) | JP2010526130A (es) |
KR (2) | KR20090130347A (es) |
CN (1) | CN101679357A (es) |
AR (1) | AR066478A1 (es) |
AU (1) | AU2008249745B2 (es) |
CA (1) | CA2685888A1 (es) |
CL (1) | CL2008001367A1 (es) |
IL (1) | IL201830A0 (es) |
MX (1) | MX2009012117A (es) |
PA (1) | PA8779801A1 (es) |
PE (1) | PE20090240A1 (es) |
TW (1) | TW200902518A (es) |
UY (1) | UY31071A1 (es) |
WO (1) | WO2008139288A2 (es) |
ZA (1) | ZA200907761B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2767478A1 (en) * | 2009-07-11 | 2011-01-20 | Bayer Pharma Aktiengesellschaft | Radiolabelling method using cycloalkyl groups |
MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
US10633366B2 (en) | 2016-06-08 | 2020-04-28 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Antibacterial compounds |
JP6755775B2 (ja) * | 2016-11-04 | 2020-09-16 | 富士アミドケミカル株式会社 | 4−フルオロイソキノリンの製法 |
CN108627579B (zh) * | 2017-03-24 | 2020-12-01 | 上海安谱实验科技股份有限公司 | Pbt制品中多环芳烃的提取方法 |
CN112236415B (zh) * | 2017-12-26 | 2023-11-14 | 赛特凯恩蒂克公司 | 氨基嘧啶的制备方法和其中间体 |
US11866431B2 (en) | 2018-11-09 | 2024-01-09 | Vivace Therapeutics, Inc. | Bicyclic compounds |
TWI849107B (zh) | 2019-04-16 | 2024-07-21 | 美商維瓦斯治療公司 | 雙環化合物 |
CN111848423B (zh) * | 2019-04-30 | 2022-10-14 | 尚科生物医药(上海)有限公司 | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
WO2022006457A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
US12084430B2 (en) | 2022-03-17 | 2024-09-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4096146A (en) * | 1968-07-02 | 1978-06-20 | Hoffmann-La Roche Inc. | 4-[5(R)-Alkyl(or alkenyl)-4(S)-quinuclidin-2(S) or 2(R)-ylcarbonyl]-quinolines, antipodes or racemates thereof and processes for their preparation |
US3869461A (en) * | 1968-07-02 | 1975-03-04 | Hoffmann La Roche | Intermediates for quinine, quinidine and derivatives thereof |
US3828048A (en) * | 1970-10-14 | 1974-08-06 | Res Et D Applic Scient Sogeras | Alkylsulfonic derivatives of quinine alkaloids |
US4002757A (en) * | 1974-12-26 | 1977-01-11 | A. H. Robins Company, Incorporated | N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides |
PT66682B (pt) * | 1976-06-18 | 1978-11-15 | Ind Biolog Francaise | /(quinolyl-4)-propyl-1/-4 piperidines leur preparation et leur utilisation comme medicaments /(quinolyl-4)-propyl/-4 piperidines leur preparation et leur utilisation comme medicaments |
NL7908031A (nl) * | 1979-11-01 | 1981-06-01 | Acf Chemiefarma Nv | Nieuwe chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werk- wijze voor het bereiden van deze verbindingen. |
FR2471981A1 (fr) * | 1979-12-21 | 1981-06-26 | Pharmindustrie | Nouveaux derives de la (piperidyl-4)-2 (quinolyl-4)-1 ethanone, produits intermediaires et procedes pour leur preparation, et leur utilisation comme medicaments |
FR2495470A1 (fr) * | 1980-12-05 | 1982-06-11 | Pharmindustrie | Nouveaux medicaments a base de derives de (quinolyl-4)-1 (piperidyl-4)-2 ethanol ou (quinolyl-4)-1 (piperidyl-4)-3 propanol |
US4757079A (en) * | 1986-06-24 | 1988-07-12 | Dynamac Corporaton | Anti-hypertensive piperidine compounds |
FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
US5260331A (en) * | 1989-01-02 | 1993-11-09 | John Wyeth & Brother Limited | Composition for treating depression with (S- or O-heteroaryl)alkyl amines |
FR2642069B1 (fr) * | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
WO1991015205A1 (fr) * | 1990-04-06 | 1991-10-17 | Eisai Co., Ltd. | Preparation buccale solide contenant un compose de catechol |
EP0533882B1 (en) * | 1991-04-03 | 2001-02-07 | Korea Research Institute Of Chemical Technology | 2-quinolinone derivatives, methods for preparing the same and fungicides and insecticides including them |
CA2075154A1 (en) * | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
GB9216297D0 (en) * | 1991-08-15 | 1992-09-16 | Ici Plc | Therapeutic agents |
FR2695126B1 (fr) * | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
DE4321030A1 (de) * | 1993-06-24 | 1995-01-05 | Bayer Ag | 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel |
GB9318691D0 (en) * | 1993-09-09 | 1993-10-27 | Merck Sharp & Dohme | Therapeutic agents |
US5512581A (en) * | 1994-07-18 | 1996-04-30 | Abbott Laboratories | Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis |
US5721103A (en) * | 1994-12-30 | 1998-02-24 | Ligand Pharmaceuticals Incorporated | Trienoic retinoid compounds and methods |
US5741789A (en) * | 1995-01-17 | 1998-04-21 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
WO1997014681A1 (en) * | 1995-10-16 | 1997-04-24 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds as h+-atpases |
DE19613329A1 (de) * | 1996-04-03 | 1997-10-09 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel |
BR9709105A (pt) * | 1996-05-20 | 1999-08-03 | Darwin Discovery Ltd | Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv |
WO1997044037A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
WO1997044339A1 (en) * | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
US6147088A (en) * | 1996-05-20 | 2000-11-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
HRP970371A2 (en) * | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
ATE300521T1 (de) * | 1996-09-25 | 2005-08-15 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
US6274598B1 (en) * | 1996-10-28 | 2001-08-14 | The United States Of America As Represented By The Secretary Of The Army | Methods for treating antibiotic-resistant infections |
US6767991B1 (en) * | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
EP1051413B1 (en) | 1998-01-26 | 2003-06-04 | SmithKline Beecham plc | Quinoline derivatives as antibacterials |
US6172087B1 (en) * | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6303627B1 (en) * | 1998-06-19 | 2001-10-16 | Eli Lilly And Company | Inhibitors of serotonin reuptake |
US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9822450D0 (en) * | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
GB9822440D0 (en) * | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
WO2000043383A1 (en) * | 1999-01-20 | 2000-07-27 | Smithkline Beecham P.L.C. | Piperidinylquinolines as protein tyrosine kinase inhibitors |
GB9910579D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
GB9910580D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
FR2798656B1 (fr) * | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
US6403610B1 (en) * | 1999-09-17 | 2002-06-11 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them |
US6794389B2 (en) * | 2000-03-31 | 2004-09-21 | Nippon Shinyaku Co., Ltd. | Quinazoline derivatives and drugs |
US6803369B1 (en) * | 2000-07-25 | 2004-10-12 | Smithkline Beecham Corporation | Compounds and methods for the treatment of neoplastic disease |
PT1650203E (pt) * | 2000-09-11 | 2008-05-13 | Novartis Vaccines & Diagnostic | Processo de preparação de derivados de benzimidazol-2-ilquinolinona |
US6603005B2 (en) * | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
US6693125B2 (en) * | 2001-01-24 | 2004-02-17 | Combinatorx Incorporated | Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders |
US6650463B2 (en) * | 2001-03-13 | 2003-11-18 | Seiko Epson Corporation | Electrophoretic display device |
US6602884B2 (en) * | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0118238D0 (en) | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
WO2003060852A2 (en) * | 2002-01-15 | 2003-07-24 | Michigan State University | Catalytic osmium-assisted oxidative cleavage of olefins |
FR2842807A1 (fr) * | 2002-07-23 | 2004-01-30 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, procede et intermediaires de preparation et compositions les renfermant |
DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
US7348434B2 (en) | 2003-08-08 | 2008-03-25 | Antony Bigot | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them |
FR2867472B1 (fr) | 2004-03-12 | 2008-07-18 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
BRPI0617376A2 (pt) * | 2005-10-13 | 2011-07-26 | Morphochem Ag | derivados de 5-quinolina tendo uma atividade antibacteriana |
-
2008
- 2008-04-29 MX MX2009012117A patent/MX2009012117A/es not_active Application Discontinuation
- 2008-04-29 EP EP08737576A patent/EP2155716A2/en not_active Withdrawn
- 2008-04-29 JP JP2010507014A patent/JP2010526130A/ja not_active Withdrawn
- 2008-04-29 WO PCT/IB2008/001076 patent/WO2008139288A2/en active Application Filing
- 2008-04-29 CA CA002685888A patent/CA2685888A1/en not_active Abandoned
- 2008-04-29 KR KR1020097025640A patent/KR20090130347A/ko not_active Application Discontinuation
- 2008-04-29 CN CN200880020428A patent/CN101679357A/zh active Pending
- 2008-04-29 AU AU2008249745A patent/AU2008249745B2/en not_active Ceased
- 2008-04-29 KR KR1020127000612A patent/KR20120011093A/ko not_active Application Discontinuation
- 2008-04-29 EP EP12165102A patent/EP2481735A1/en not_active Withdrawn
- 2008-05-07 PE PE2008000800A patent/PE20090240A1/es not_active Application Discontinuation
- 2008-05-07 AR ARP080101937A patent/AR066478A1/es not_active Application Discontinuation
- 2008-05-08 US US12/117,071 patent/US20080280879A1/en not_active Abandoned
- 2008-05-08 UY UY31071A patent/UY31071A1/es not_active Application Discontinuation
- 2008-05-08 TW TW097117046A patent/TW200902518A/zh unknown
- 2008-05-09 PA PA20088779801A patent/PA8779801A1/es unknown
- 2008-05-09 CL CL2008001367A patent/CL2008001367A1/es unknown
-
2009
- 2009-10-29 IL IL201830A patent/IL201830A0/en unknown
- 2009-11-04 ZA ZA200907761A patent/ZA200907761B/xx unknown
-
2010
- 2010-12-20 US US12/972,620 patent/US20110092480A1/en not_active Abandoned
-
2011
- 2011-11-22 US US13/302,151 patent/US20120065188A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PE20090240A1 (es) | 2009-03-19 |
US20110092480A1 (en) | 2011-04-21 |
US20080280879A1 (en) | 2008-11-13 |
KR20120011093A (ko) | 2012-02-06 |
CN101679357A (zh) | 2010-03-24 |
IL201830A0 (en) | 2010-06-16 |
ZA200907761B (en) | 2010-08-25 |
MX2009012117A (es) | 2009-11-23 |
WO2008139288A3 (en) | 2009-03-26 |
CL2008001367A1 (es) | 2008-11-07 |
TW200902518A (en) | 2009-01-16 |
WO2008139288A2 (en) | 2008-11-20 |
KR20090130347A (ko) | 2009-12-22 |
JP2010526130A (ja) | 2010-07-29 |
EP2481735A1 (en) | 2012-08-01 |
EP2155716A2 (en) | 2010-02-24 |
UY31071A1 (es) | 2009-01-05 |
PA8779801A1 (es) | 2009-01-23 |
US20120065188A1 (en) | 2012-03-15 |
AU2008249745A1 (en) | 2008-11-20 |
AU2008249745B2 (en) | 2012-01-12 |
CA2685888A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR066478A1 (es) | Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones | |
AR118123A2 (es) | Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación | |
AR060562A1 (es) | Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas. | |
AR060605A1 (es) | Derivados de diazepano como antagonistas del receptor ccr2 | |
AR060401A1 (es) | Derivados de cromen-2-ona | |
AR079231A1 (es) | Derivados de imidazoquinolina | |
AR059458A1 (es) | Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos | |
AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
CO6170061A1 (es) | Compuestos de pirandiona, tiopirandiona y ciclohexantriona utiles como herbicidas, procesos para su preparacion, intermediarios utiles en su preparacion, metodos para controlar hierbas y malezas en cultivos de plantas utiles utilizando dichos herbici | |
AR063684A1 (es) | Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc. | |
AR088449A1 (es) | Benzilindazoles sustituidos | |
PE20141935A1 (es) | Compuestos de dioxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso | |
PE20130155A1 (es) | Derivados de ariletinilo | |
ES2529233T3 (es) | Compuestos tetrazol como bloqueadores de canales de calcio | |
ECSP109932A (es) | Compuestos de biciclolactama sustituida | |
AR064635A1 (es) | Derivados de benzotiazolona | |
PE20061106A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
AR072052A1 (es) | Derivados de indano como reguladores del receptor ampa | |
AR054789A1 (es) | Antagonistas del receptor 1 de triazolopiridina canabinoide | |
AR066492A1 (es) | Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres. | |
AR070463A1 (es) | Compuestos de amina y eter que modulan el receptor cb2 | |
AR065280A1 (es) | Agentes antiparasitarios | |
AR061651A1 (es) | Analogos de piridina ii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |